---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062968"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:57:43.841020+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kintara suspends VAL-083 after GBM AGILE failure; Q1 net loss $3M, cash $0.2M

## Summary
- Topline GBM AGILE results showed VAL-083 did not perform better than standard of care; development suspended.
- Focus shifts to REM-001 for cutaneous metastatic breast cancer; SBIR grant of $2.0M from NIH to support study.
- Cash and cash equivalents $0.2M at Sep 30, 2023; raised ~$1.0M net in Nov 2023 via ATM facility.
- Net loss $3.0M ($1.83/share) vs $4.6M ($3.39/share) in prior-year Q1; R&D and G&A expenses decreased.
- Company evaluating strategic options to maximize shareholder value.

## SEC filing metadata
- accession: 0000950170-23-062968
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017023062968/0000950170-23-062968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017023062968/ktra-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062968
- JSON: https://secwatch.observer/filing/0000950170-23-062968.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062968.txt

## Key facts
- Earnings Releases
  TuHURA Biosciences, Inc./NV reported fiscal first quarter ended September 30, 2023 results: net income approximately $3.0 million, or $1.83 per share, EPS $1.83 per share (basic and diluted loss per share from net loss attributable to common stockholders).
  - Period: fiscal first quarter ended September 30, 2023
  - Net income: approximately $3.0 million, or $1.83 per share
  - EPS: $1.83 per share (basic and diluted loss per share from net loss attributable to common stockholders)
  - Result: reported results
  source text: For the three months ended September 30, 2023, Kintara reported a net loss of approximately $3.0 million, or $1.83 per share, compared to a net loss of approximately $4.6 million, or $3.39 per share, for the three months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017023062968/0000950170-23-062968-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.